Fluticasone_furoate has been approved in the United States and in the European Union

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


fluticasone_furoate studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
FFU105924 IV A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis
FFU105927 IV A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis
FFR100010 III A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg* and 100mcg* for 2 Weeks in Pediatric Subjects Ages 2 to <12 Years with Seasonal Allergic Rhinitis (SAR)
FFR100012 III A randomized, double-blind, parallel group, placebo controlled, 6-week study of the effect of fluticasone furoate aqueous nasal spray 100mcg* QD on the hypothalamic pituitary adrenocortical (HPA) axis in children 2 to <12 years of age with perennial allergic rhinitis (PAR)
FFR100652 III Clinical Evaluation of GW685698 for Seasonal Allergic Rhinitis - A Placebo-Controlled Study to Determine the Non-Inferiority of GW685698 over Fluticasone Propionate Using a Double-Blind Manner -
FFR100688 III Clinical Evaluation of GW685698 for Perennial Allergic Rhinitis -Long-Term Safety Study -
FFR101747 III A Randomised, Double-Blind, Placebo-Controlled, Two-Week Crossover, Knemometric Assessment of the Effect of Fluticasone Furoate Nasal Spray 100mcg* Once Daily on Short-Term Growth in Children Aged 6 to 11 Years with Seasonal and/or Perennial Allergic Rhinitis
FFR101816 III A Randomized, Double Blind, Placebo-Controlled, Single-Dose, Parallel-Group Study to Evaluate the Onset of Action of a Single Dose of Intranasal GW685698X Aqueous Nasal Spray 100mcg* in Adolescent and Adult Subjects (>/12 years of age) with Seasonal Allergic Rhinitis Exposed to Ragweed Pollen in an Allergen Challenge Chamber
FFR102123 III A randomised double-blind placebo controlled parallel group multicentre long term study to evaluate the safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100mcg* for 52 weeks in adult and adolescent subjects with perennial allergic rhinitis.
FFR103184 III A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Two Week Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis in Europe
FFR104503 III A Randomized, Open Label, Active Controlled (Mometasone Furoate Aqueous Nasal Spray [Nasonex®] 200mcg QD), Parallel Group, Multi-Center, 52-Week Study to Assess the Long Term Safety of GW685698X Aqueous Nasal Spray 100mcg* QD via Nasal Biopsy in Subjects ?18 Years of Age with Perennial Allergic Rhinitis (PAR)
FFR104861 III A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* for 2 Weeks in Adult and Adolescent Subjects >/12 Years of Age with Seasonal Allergic Rhinitis
FFR106080 III A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* for 6 Weeks in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR)
FFR20002 III A randomized, double-blind, parallel group, placebo and active (prednisone) controlled, 6-week study of the effect of fluticasone furoate aqueous nasal spray 100mcg* QD on the hypothalamic pituitary adrenocortical (HPA) axis in adolescents and adults 12 to 65 years of age with perennial allergic rhinitis (PAR)
FFR30002 III A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* for 4 Weeks in Adult and Adolescent Subjects (>/12 years of age) with Perennial Allergic Rhinitis (PAR)
FFR30003 III A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis
FFR30006 III A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis (VMR)
FFR30007 III A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg* for 4 Weeks in Adult and Adolescent Subjects (12 years of age and older) with Vasomotor Rhinitis
FFR30008 III A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mg* and 100mcg* for 12 Weeks in Pediatric Subjects Ages 2 to <12 Years with Perennial Allergic Rhinitis (PAR)
FFU108556 III Study FFU108556, A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis
FFU109045 III Study FFU109045, A Comparison of Fluticasone Furoate Nasal Spray (FFNS) versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis
FFU109047 III Study FFU109047, A Comparison of Fluticasone Furoate Nasal Spray (FFNS) versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis
FFR100650 II Clinical Evaluation of GW685698 for Perennial Allergic Rhinitis - Dose-Finding Study by Double-Blind Comparative Method -
FFR20001 II A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of Once Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 50mcg*, 100mcg*, 200mcg*, or 400mcg* for 14 days in Adult and Adolescent Subjects with Seasonal Allergic Rhinitis.